• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".科恩等人对关于文章《血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用与 COVID-19 住院高血压患者死亡率的关联》的信件的回应
Circ Res. 2020 Jun 5;126(12):e140-e141. doi: 10.1161/CIRCRESAHA.120.317205. Epub 2020 Jun 4.
2
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
3
Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).致编辑的信：回应《血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在2019冠状病毒病大流行期间可能对糖尿病患者有害》（库尔等人）
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):525-526. doi: 10.1016/j.dsx.2020.04.054. Epub 2020 May 5.
4
ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?对抗新冠病毒：血管紧张素轴抑制在新型冠状病毒感染中能发挥作用吗？
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.
5
Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?肾素-血管紧张素-醛固酮系统抑制剂用于治疗新型冠状病毒肺炎？
CMAJ. 2020 Jun 29;192(26):E728. doi: 10.1503/cmaj.76023.
6
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
7
COVID-19 and cardiovascular comorbidities: An update.新型冠状病毒肺炎与心血管合并症：最新进展
Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repc.2020.06.013. Epub 2020 Jul 9.
8
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与冠状病毒
J Hypertens. 2020 Jun;38(6):1190-1191. doi: 10.1097/HJH.0000000000002469.
9
Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.致编辑的信：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在基于新冠病毒疾病合并症的宿主风险评分制定中的作用
Crit Care. 2020 May 19;24(1):242. doi: 10.1186/s13054-020-02903-9.
10
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.

引用本文的文献

1
Identification and Development of Therapeutics for COVID-19.新型冠状病毒肺炎治疗方法的识别与开发
mSystems. 2021 Dec 21;6(6):e0023321. doi: 10.1128/mSystems.00233-21. Epub 2021 Nov 2.
2
Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.住院期间停用血管紧张素受体阻滞剂或血管紧张素转换酶抑制剂对 COVID-19 患者死亡率的影响：一项回顾性队列研究。
BMC Med. 2021 May 12;19(1):118. doi: 10.1186/s12916-021-01992-9.
3
Renin-angiotensin system blockade in the COVID-19 pandemic.新型冠状病毒肺炎大流行中的肾素-血管紧张素系统阻断
Clin Kidney J. 2021 Feb 2;14(Suppl 1):i48-i59. doi: 10.1093/ckj/sfab026. eCollection 2021 Mar.
4
Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.肾素-血管紧张素系统及其调节剂在新冠疫情期间的争议性作用
Front Physiol. 2021 Feb 22;12:624052. doi: 10.3389/fphys.2021.624052. eCollection 2021.
5
Identification and Development of Therapeutics for COVID-19.新型冠状病毒肺炎治疗方法的识别与开发
ArXiv. 2021 Mar 3:arXiv:2103.02723v3.
6
Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.肾素-血管紧张素系统阻滞剂与 COVID-19 易感性的关系：一项国际、开放科学、队列分析。
Lancet Digit Health. 2021 Feb;3(2):e98-e114. doi: 10.1016/S2589-7500(20)30289-2. Epub 2020 Dec 17.
7
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.随机排除和延长 ACE 抑制剂和 ARBs 在冠状病毒 2019（REPLACE COVID）试验方案中的作用。
J Clin Hypertens (Greenwich). 2020 Oct;22(10):1780-1788. doi: 10.1111/jch.14011. Epub 2020 Sep 16.

本文引用的文献

1
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
2
ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?对抗新冠病毒：血管紧张素轴抑制在新型冠状病毒感染中能发挥作用吗？
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.
3
COVID-19, ACE2, and the cardiovascular consequences.新型冠状病毒肺炎、血管紧张素转化酶 2 与心血管系统并发症
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090. doi: 10.1152/ajpheart.00217.2020. Epub 2020 Mar 31.
4
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.在对COVID-19中的RAS阻断进行快速判断之前的可靠科学依据。
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716. doi: 10.2215/CJN.03530320. Epub 2020 Mar 27.
5
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations.新型冠状病毒肺炎死亡率与肾素-血管紧张素系统之间是否存在关联？呼吁开展流行病学研究。
Clin Infect Dis. 2020 Jul 28;71(15):870-874. doi: 10.1093/cid/ciaa329.
6
Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.中国高血压现状：2012-2015 年中国高血压调查结果。
Circulation. 2018 May 29;137(22):2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380. Epub 2018 Feb 15.
7
Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010.美国高血压成年人降压药物使用和血压控制趋势：2001 至 2010 年国家健康和营养调查。
Circulation. 2012 Oct 23;126(17):2105-14. doi: 10.1161/CIRCULATIONAHA.112.096156.
8
Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias.在队列研究中，随时间变化的研究记录和暴露因素很容易成为不同类型且可避免的偏倚来源。
J Clin Epidemiol. 2012 Nov;65(11):1171-80. doi: 10.1016/j.jclinepi.2012.04.008.

Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".

作者信息

Cohen Jordana B, Hanff Thomas C, South Andrew M, Sparks Matthew A, Hiremath Swapnil, Bress Adam P, Byrd J Brian, Chirinos Julio A

机构信息

From the Renal-Electrolyte and Hypertension Division (J.B.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Department of Biostatistics, Epidemiology, and Informatics (J.B.C., T.C.H.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.

出版信息

Circ Res. 2020 Jun 5;126(12):e140-e141. doi: 10.1161/CIRCRESAHA.120.317205. Epub 2020 Jun 4.

DOI:10.1161/CIRCRESAHA.120.317205
PMID:32496917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7265880/
Abstract
摘要